PHA 568487

PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 nAchR) [1][2].PHA 568487 reduces neuroinflammation and oxidative stress[2]. PHA-568487 has rapid brain penetration[3].

Product Specifications

CAS Number

[527680-57-5]

UNSPSC

12352005

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pha-568487.html

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

OC(/C=C/C(O)=O)=O.O=C(C1=CC=C(OCCO2)C2=C1)N[C@@H]3C4CCN(CC4)C3

Molecular Formula

C20H24N2O7

Molecular Weight

404.41

References & Citations

[1]F Barclay Shilliday, et al. Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett. 2010 Aug;4 (3) :162-72.|[2]Zhenying Han, et al. Alpha-7 nicotinic acetylcholine receptor agonist treatment reduces neuroinflammation, oxidative stress, and brain injury in mice with ischemic stroke and bone fracture. J Neurochem. 2014 Nov;131 (4) :498-508.|[3]Dingquan Zou, et al.Activation of Alpha-7 Nicotinic Acetylcholine Receptor Reduces Brain Edema in Mice with Ischemic Stroke and Bone Fracture. Mol Neurobiol. 2017 Dec;54 (10) :8278-8286.|[4]Lorena Colás, et al. In vivo imaging of Α7 nicotinic receptors as a novel method to monitor neuroinflammation after cerebral ischemia. Glia. 2018 Aug;66 (8) :1611-1624.